Hypoxia in fish

Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021

Retrieved on: 
Thursday, June 3, 2021
Chemistry, Enzymes, Acetic acids, Physical sciences, Transcription factors, Hypoxia-inducible factor, Vadadustat, Procollagen-proline dioxygenase, European Renal Association – European Dialysis and Transplant Association, Hydroxylation, Hypoxia in fish, Ethylenediaminetetraacetic acid

For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/ .

Key Points: 
  • For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/ .
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.
  • For more information, please visit our website at www.akebia.com , which does not form a part of this release.
  • Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, May 27, 2021
Branches of biology, Biology, Cell biology, Transcription factors, Hypoxia-inducible factor, Growth factors, CTGF, Myelodysplastic syndrome, Roxadustat, Hypoxia in fish, HIF, Dysplasia

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

Otsuka and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia’s Vadadustat

Retrieved on: 
Tuesday, March 30, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Enzymes, Chemistry, Physical sciences, Acetic acids, Pyridines, Vadadustat, Hypoxia-inducible factor, Otsuka Pharmaceutical, Hydroxylation, Procollagen-proline dioxygenase, Hypoxia in fish, HIF prolyl-hydroxylase inhibitor, Akebia’s Vadadustat, Otsuka

In 2016, Otsuka and Akebia signed a collaboration and license agreement for vadadustat in the U.S.

Key Points: 
  • In 2016, Otsuka and Akebia signed a collaboration and license agreement for vadadustat in the U.S.
  • The two companies subsequently signed a collaboration and license Agreement in 2017 for vadadustat in certain other areas.
  • Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.
  • Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI).

At a CAGR of 7.7%, Global Hypoxia Chamber Market to Surpass US$ 100.6 Million by the End of 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Tuesday, February 16, 2021
General Health, Health, Oncology, Medical devices, Oxygen, Aquatic ecology, Chemical oceanography, Environmental science, Hypoxia in fish, Stemcell Technologies, Financial market, Physical sciences, Earth sciences, Natural sciences

According to Coherent Market Insights, the global hypoxia chamber market is estimated to be valued at US$ 59.9 million in 2020 and is expected to exhibit a CAGR of 7.7% during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global hypoxia chamber market is estimated to be valued at US$ 59.9 million in 2020 and is expected to exhibit a CAGR of 7.7% during the forecast period (2020-2027).
  • Furthermore, key players operating in the global hypoxia chamber market are focusing on adoption of inorganic growth strategies such as agreements and collaborations to increase their presence in the global market.
  • The global hypoxia chamber market is expected to exhibit a CAGR of 7.7% during the forecast period owing to adoption of expansion strategies by market players.
  • Key players operating in the global hypoxia chamber market are Baker, STEMCELL Technologies Inc, BioSpherix Ltd, Plas-Labs, HypOxygen, Coy Labs, Oxford Optronix Ltd, Scintica Instrumentation Inc., CytoSMART Technologies B.V.

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
Friday, February 12, 2021
Branches of biology, Biology, Cell biology, Transcription factors, Hypoxia-inducible factor, Growth factors, CTGF, Myelodysplastic syndrome, Roxadustat, Hypoxia in fish, HIF, Dysplasia

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
Friday, November 6, 2020
Branches of biology, Biology, Cell biology, Transcription factors, Hypoxia-inducible factors, Growth factors, CTGF, Myelodysplastic syndrome, Roxadustat, Hypoxia in fish, HIF, Dysplasia

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics.
  • The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia.

Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined

Retrieved on: 
Friday, October 9, 2020
Enzymes, Chemistry, Chemical compounds, Acetic acids, Transcription factors, Hypoxia-inducible factors, Vadadustat, Procollagen-proline dioxygenase, Hydroxylation, Hypoxia in fish, HIF prolyl-hydroxylase inhibitor, HIF prolyl-hydroxylase

ET to review highlights of the Phase 3 vadadustat data presentations from ASN Kidney Week.

Key Points: 
  • ET to review highlights of the Phase 3 vadadustat data presentations from ASN Kidney Week.
  • After the webcast concludes, a replay of the event will be available at that same location until October 29, 2020.
  • Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 1, 2020
Branches of biology, RTT, Biology, Medical specialties, Transcription factors, Hypoxia-inducible factors, Growth factors, CTGF, Myelodysplastic syndrome, Roxadustat, Hypoxia in fish, Anemia

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics.
  • The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia.

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 27, 2020
Branches of biology, Medical specialties, RTT, Biology, Transcription factors, Hypoxia-inducible factors, Growth factors, CTGF, Myelodysplastic syndrome, Roxadustat, Dysplasia, Hypoxia in fish

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics.
  • The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia.

Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results

Retrieved on: 
Tuesday, May 5, 2020
Enzymes, Catalysts, Acetic acids, Transcription factors, Hypoxia-inducible factors, Vadadustat, RTT, Procollagen-proline dioxygenase, Anemia, Hydroxylation, Hypoxia in fish, HIF prolyl-hydroxylase inhibitor

As a result, we continue to actively monitor and assess the potential impact of COVID-19 on our business and operations while continuing to support patients."

Key Points: 
  • As a result, we continue to actively monitor and assess the potential impact of COVID-19 on our business and operations while continuing to support patients."
  • Dr. Wolf is a leading clinical nephrologist and physician-scientist in the fields of disordered mineral metabolism and cardiovascular disease in patients with CKD.
  • Net Loss:Net loss was $60.7 millionfor the first quarter of 2020compared to $72.4 million for the first quarter of 2019.
  • Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in global Phase 3 development for the treatment of anemia due to CKD.